IONESCO trial of neoadjuvant durvalumab in NSCLC terminated early

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 24 / Springer Healthcare

IONESCO trial of neoadjuvant durvalumab in NSCLC terminated early

Oncology Lung Cancer ESMO-2020

Description

Marie Wislez presents preliminary data from the IONESCO study evaluating the feasibility of neoadjuvant durvalumab in patients with early-stage non-small-cell lung cancer, and discusses the next steps in light of the premature closure.

Related Content

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.